Nitto Denko Corp., of Osaka, Japan, reported preliminary results from ongoing phase Ib/II studies showing that ND-L02-s0201, its targeted siRNA lipid nanoparticle, was well tolerated in advanced fibrosis patients, with histological improvement of fibrosis observed. ND-L02-s0201 has been granted two FDA fast track designations for non-alcoholic steatohepatitis and hepatitis C virus liver fibrosis.